August 28, 2013
Takeda Pharmaceutical announced on August 27 that it has initiated TOMMORROW, a global PIII clinical trial that will investigate the efficacy of its diabetes treatment Actos (pioglitazone) at delaying the onset of Alzheimer’s disease (AD). The trial is being conducted...read more